Efficacy of Different Doses of Nalbuphine Combined with Sufentanil in Patient-Controlled Intravenous Analgesia After Laparoscopic Colorectal Cancer Surgery

A Randomized, Controlled, Double-Blind Trial Investigating the Efficacy of Different Doses of Nalbuphine Combined with Sufentanil for Postoperative Patient-Controlled Intravenous Analgesia After Laparoscopic Colorectal Cancer Surgery

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500101701

Enrollment

Unknown

Registered

2025-04-28

Start date

2025-05-05

Completion date

Unknown

Last updated

2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

control group:Sufentanil (S group): 2.5 µ g/kgSufentanil

LNS group:0.5 mg/kg nalbuphine+1.25 µ g/kg sufentanil

MNS group:1.0 mg/kg nalbuphine+1.25 µ g/kg sufentanil

HNS group:1.5 mg/kg nalbuphine+1.25 µ g/kg sufentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Age range: 18-85 years old. 2 Diagnosed with colorectal cancer and scheduled for laparoscopic surgery. 3 ASA grades I-III. 4 Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1 Have a history of opioid or alcohol abuse. 2 Has severe heart, lung, liver, and kidney dysfunction. 3 Individuals allergic to opioid drugs. 4 Having mental illness or cognitive impairment. 5 Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Postoperative pain assessment;	—

Secondary

Measure	Time frame
Visual Analog Scale (VAS) scores in resting and active states;	—

Countries

China

Contacts

Public Contactlibingchuan

Department of Anesthesiology, Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine

839417563@qq.com+86 138 0973 4202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026